Evidence map›Paper›PMID 28769133›Full record

ArticleReumatologia

The prevalence of ANA antibodies, anticentromere antibodies, and anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome compared to patients with dryness symptoms without primary Sjögren's syndrome confirmation.

Maria Maślińska, Małgorzata Mańczak, Bożena Wojciechowska, Brygida Kwiatkowska

Open access · diamondAbstract read
In one paragraph

Article in Reumatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Maria MaślińskaEarly Arthritis Clinic, National Institute of Geriatrics, Rehabilitation and Rheumatology, Warsaw, Poland.
Małgorzata MańczakDepartment of Gerontology and Public Health, National Institute of Geriatrics, Rehabilitation and Rheumatology, Warsaw, Poland.
Bożena WojciechowskaCentral Clinical Laboratory, National Institute of Geriatrics, Rehabilitation and Rheumatology, Warsaw, Poland.
Brygida KwiatkowskaEarly Arthritis Clinic, National Institute of Geriatrics, Rehabilitation and Rheumatology, Warsaw, Poland.
National Institute of Geriatrics, Rheumatology and Rehabilitation · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesOur study analyses the prevalence of ANA, anti-SS-A, anti-SS-B, and ACA and ACPA antibodies in patients with pSS and with dryness symptoms without pSS confirmation, and the association of ACPA and ACA antibodies with specific clinical symptoms. MATERIALS AND

methods113 patients were divided into two groups: I - with diagnosed pSS (

results88% of group I had ANA antibodies (1 : 320 titre), 5.3% at 1 : 160. Anti-SS-A antibodies were present in 88% of group I, including all ANA 1 : 160. Anti-SS-A antibodies positively correlated with greater and moderate activity of ESSDAI 5 (

conclusionsANA antibodies should also be considered in a titre of less than 1 : 320, but the presence of anti-SS-A antibodies is still the most important immunological marker for pSS. Anti-SS-A antibodies correlate with higher disease activity (ESSDAI ≥ 5) and higher FS. The presence of the anti-SS-B antibody was significantly affected by higher activity of the disease. The incidence of arthritis was higher in patients with ACPA+ pSS compared to ACPA- (

Indexed as

anticentromere antibodiesanticyclic citrullinated antibodiesSjögren’s syndrome

Identifiers

PMID28769133
PMCPMC5534504
OpenAlexW2738197178

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.